Academia–Industry Partnerships: Are we ready for new models of partnership?: The point of view of the EORTC, an academic clinical cancer research organisation
- 31 January 2013
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 49 (1), 1-7
- https://doi.org/10.1016/j.ejca.2012.09.027
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Open Clinical Trial Data for All? A View from RegulatorsPLoS Medicine, 2012
- Public-private partnerships need honest brokeringNature Medicine, 2012
- Application of cost–effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemiaPharmacogenomics, 2011
- Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO modelBlood, 2011
- When Sunlight Fails to Disinfect: Understanding the Perverse Effects of Disclosing Conflicts of InterestJournal of Consumer Research, 2011
- Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005Journal of Clinical Oncology, 2009
- Keeping faith with trial volunteersNature, 2007
- Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumoursEuropean Journal Of Cancer, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I StudiesJournal of Clinical Oncology, 2003